Biotech Values

[lumpy9200]

CAMH

"If sales were ramping quicker I would say competitors might have a problem encroaching their territory. But since the ramp is slow other competitors might give them a problem."

I won't discuss VICOR as the likely scam it seems to be, as apljack has clearly made the case for that.

What is worth noting is the ramp in sales for CAMH. 2008 revenues have been estimated between $36-42 million. Quite a jump from 2007 expected revs, which dwarf 2006. The product is starting to sell.

I'll leave the CAMH thread for now to avoid monopolizing the board on one topic. I will reiterate that I've been pounding the table on CAMH here for a long time now, and find the case to own shares gets more compelling every month. It should be noted that CAMH has applied for, and qualifies for, NASDAQ small market listing on September 27th (90 trading days of closing bid over $4.00). There is "anecdotal" evidence that a few large institutions are ready to buy shares pending the listing. Additionally, I have particularly strong reasons to believe that STJ and CAMH will expand their marketing agreement to Europe before summer's end.

Best regards,
Geoff